Ongoing studies on colchicine for cardiovascular indications
| Trial | Registration | Setting | Study type | Target sample | Drugs | Primary outcome |
| LoDoCo2 | ACTRN12614000093684 | Stable CAD | RCT, phase 3 | 5500 | Colchicine 0.5 mg/day | Composite of cardiovascular death, MI, ischaemic stroke and ischaemia-driven coronary revascularisation |
| COACS | ClinicalTrials.gov identifier: NCT01906749 | ACS | RCT, phase 3 | 500 | Colchicine 0.5 mg/day | Overall mortality, new acute coronary syndrome and ischaemic stroke |
| CLEAR-SYNERGY | ClinicalTrials.gov identifier: NCT03048825 | STEMI with PCI | Randomised, blinded, double-dummy, 2×2 factorial design trial of colchicine versus placebo and spironolactone versus placebo | 4000 | Colchicine 0.5 mg/day; spironolactone 25 mg/day | MACE at 1 year; composite of cardiovascular death, recurrent MI, or stroke; composite of cardiovascular death or new or worsening heart failure |
| CONVINCE | ClinicalTrials.gov identifier: NCT02898610 | Transient ischaemic attack; stroke | Open label, phase 3 | 2623 | Colchicine (0.5 mg/day) | Recurrence of non-fatal ischaemic stroke; non-fatal major cardiac event; vascular death |
The LoDoCo2 trial: Low-Dose Colchicine for secondary prevention of cardiovascular disease.
ACS, acute coronary syndrome; CAD, coronary artery disease; CLEAR-SYNERGY, Colchicine and Spironolactone in Patients With STEMI/SYNERGY Stent Registry; COACS, Colchicine for Acute Coronary Syndromes; CONVINCE, Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke; MACE, major adverse cardiac events; MI, myocardial infarction; PCI, percutaneous coronary intervention; RCT, randomised controlled trial; STEMI, ST-elevation myocardial infarction.